Get all your news in one place.
100's of premium titles.
One app.
Start reading
International Business Times
International Business Times
Business
AFP News

Eli Lilly Weight Loss Drug Beats Ozempic In Head-to-head Study

At 12 months, the average patient on Eli Lilly's new drug Mounjaro lost seven percent more weight than the average for Ozempic (Credit: AFP)

Patients taking Eli Lilly's new drug Mounjaro achieved significantly greater weight loss than those on Novo Nordisk's Ozempic, a head-to-head study published Monday showed.

Researchers analyzed the electronic health records of more than 18,000 US patients between May 2022 and September 2023 to compare outcomes among those receiving the two injected medicines, and published the results in JAMA Internal Medicine.

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.